Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript
10:31pm, Tuesday, 29'th Oct 2024
Exelixis, Inc. (NASDAQ:EXEL ) Q3 2024 Earnings Conference Call October 29, 2024 5:00 PM ET Company Participants Varant Shirvanian - Director, IR Michael Morrissey - President & CEO Christopher Senner
Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to Say
07:31pm, Tuesday, 29'th Oct 2024
The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street est
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates
06:20pm, Tuesday, 29'th Oct 2024
Exelixis (EXEL) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.10 per share a year ago.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
10:51am, Thursday, 24'th Oct 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
10:11am, Thursday, 24'th Oct 2024
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position EXEL, B
Here's Why Exelixis (EXEL) is a Great Momentum Stock to Buy
01:01pm, Wednesday, 23'rd Oct 2024
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
1 No-Brainer Stock to Buy With $40
09:53am, Wednesday, 23'rd Oct 2024
The midcap biotech just became an even better buy.
Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
11:06am, Tuesday, 22'nd Oct 2024
Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Attractive Biotechs With Recent Positives
04:17pm, Monday, 21'st Oct 2024
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lu
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:46am, Monday, 21'st Oct 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or CSLLY: Which Is the Better Value Stock Right Now?
12:45pm, Friday, 18'th Oct 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two companies is the
Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials
04:41am, Friday, 18'th Oct 2024
Exelixis' stock has surged 51% since July 2023, significantly outperforming broader markets and breaking out of a five-year stagnation. Cabometyx, EXEL's primary revenue driver, continues to excel in
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
12:06pm, Wednesday, 16'th Oct 2024
Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Exelixis Gets Favorable Ruling in Patent Litigation With MSN
10:51am, Wednesday, 16'th Oct 2024
The Delaware District Court ruled in EXEL's favor, rejecting MSN's challenge to three patents related to cabozantinib.
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
04:05pm, Tuesday, 15'th Oct 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At
